Your browser doesn't support javascript.
Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment.
Harke, Nina N; Wagner, Christian; Hermann, Robert M; Hadaschik, Boris A; Radtke, Jan Philipp; Altay-Langguth, Alev; Aufderklamm, Stefan; Bach, Christian; Becker-Schiebe, Martina; Blana, Andreas; Bruns, Frank; Buse, Stephan; Combs, Stephanie E; Engels, Christina L; Ezzibdeh, Emad; Fiedler, Marcel; Fischer, Laura-Anna; Farzat, Mahmoud; Frismann, Alexander; Heck, Matthias M; Henkenberens, Christoph; Roesch, Marie C; Käding, Christoph; Klautke, Gunther; Krausewitz, Philipp; Kuczyk, Markus A; Leitsmann, Conrad; Lettmaier, Sebastian; Mahjoub, Samy; Manseck, Andreas; Medenwald, Daniel; Meyer, Andreas; Micke, Oliver; Moritz, Rudolf; Ott, Marcel; Peters, Inga; Pokupic, Sasa; Porres, Daniel; Preisser, Felix; Reichel, Kathrin; Schneider, Andreas; Schwentner, Christian; Scobioala, Sergiu; Truss, Michael; Wegener, Daniel; Wezel, Felix; Willborn, Kay; Witt, Jörn H; Wittig, Andrea; Wittlinger, Michael.
  • Harke NN; Department of Urology, Hannover Medical School, Hannover, Germany.
  • Wagner C; Department of Urology, St. Antonius Hospital, Gronau, Germany.
  • Hermann RM; Center of Radiotherapy, Bremen, Germany.
  • Hadaschik BA; Department of Urology, University of Duisburg-Essen, Essen, Germany.
  • Radtke JP; Department of Urology, University of Duisburg-Essen, Essen, Germany.
  • Altay-Langguth A; Department of Radiotherapy, University Hospital, Goethe University, Frankfurt am Main, Germany.
  • Aufderklamm S; Department of Urology, Eberhard Karls University Tuebingen, Tuebingen, Germany.
  • Bach C; Department of Urology, RWTH Aachen University, Aachen, Germany.
  • Becker-Schiebe M; Department of Radiotherapy, Klinikum Braunschweig, Braunschweig, Germany.
  • Blana A; Department of Urology, Fürth Hospital, Fürth, Germany.
  • Bruns F; Department of Radiotherapy, Hannover Medical School, Hannover, Germany.
  • Buse S; Department of Urology, Alfried Krupp Krankenhaus, Essen, Germany.
  • Combs SE; Department of Radiation Oncology, Technical University of Munich, Munich, Germany.
  • Engels CL; Institute of Radiation Medicine, Helmholtz Zentrum München (HMGU), Oberschleißheim, München, Germany.
  • Ezzibdeh E; Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich, Germany.
  • Fiedler M; Department of Urology, Municipal Hospital Karlsruhe, Karlsruhe, Germany.
  • Fischer LA; Department of Urology, Klinikum Lüneburg, Lueneburg, Germany.
  • Farzat M; Department of Urology, SLK Kliniken Heilbronn, Heilbronn, Germany.
  • Frismann A; Department of Radiotherapy, University Medical Center Goettingen, Goettingen, Germany.
  • Heck MM; Department of Urology, Diakonie Klinikum, Siegen, Germany.
  • Henkenberens C; Department of Radiotherapy, University of Leipzig, Leipzig, Germany.
  • Roesch MC; Department of Urology, Technical University of Munich, Munich, Germany.
  • Käding C; Department of Radiotherapy, University Hospital Bonn, Bonn, Germany.
  • Klautke G; Department of Urology, University Hospital Schleswig-Holstein, Luebeck, Germany.
  • Krausewitz P; Department of Urology, University of Medicine Greifswald, Greifswald, Germany.
  • Kuczyk MA; Clinic for Radiation Oncology, Chemnitz Medical Center, Chemnitz, Germany.
  • Leitsmann C; Department of Urology, University Hospital Bonn, Bonn, Germany.
  • Lettmaier S; Department of Urology, Hannover Medical School, Hannover, Germany.
  • Mahjoub S; Department of Urology, University Medical Center Goettingen, Goettingen, Germany.
  • Manseck A; Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, Germany.
  • Medenwald D; Department of Urology, Hannover Medical School, Hannover, Germany.
  • Meyer A; Department of Urology, Klinikum Ingolstadt, Ingolstadt, Germany.
  • Micke O; Department of Radiation Therapy, University Hospital Halle/Saale, Halle, Germany.
  • Moritz R; Center of Radiotherapy Hildesheim/Goslar, Hildesheim, Germany.
  • Ott M; Department of Radiotherapy, Franziskus Hospital Bielefeld, Bielefeld, Germany.
  • Peters I; Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany.
  • Pokupic S; Center of Radiotherapy Wolfsburg, Wolfsburg, Germany.
  • Porres D; Department of Urology, Hannover Medical School, Hannover, Germany.
  • Preisser F; Department of Urology, Asklepios Klinikum Harburg, Hamburg, Germany.
  • Reichel K; Department of Urology, Klinikum Leverkusen, Leverkusen, Germany.
  • Schneider A; Department of Urology, University Hospital, Goethe University, Frankfurt am Main, Germany.
  • Schwentner C; Department of Urology, Sana Klinikum Hof, Hof, Germany.
  • Scobioala S; Department of Urology, Main-Kinzig-Kliniken Standort Gelnhausen, Gelnhausen, Germany.
  • Truss M; Department of Urology, Diakonieklinikum Stuttgart, Stuttgart, Germany.
  • Wegener D; Department of Radiation Oncology, University Hospital Muenster, Muenster, Germany.
  • Wezel F; Department of Urology, Klinikum Dortmund, Dortmund, Germany.
  • Willborn K; Department of Radiation Oncology, University of Tübingen, Tuebingen, Germany.
  • Witt JH; Department of Urology, Ulm University Hospital, Ulm, Germany.
  • Wittig A; Department of Radiotherapy, Pius Hospital Oldenburg, Oldenburg, Germany.
  • Wittlinger M; Department of Urology, St. Antonius Hospital, Gronau, Germany.
PLoS One ; 17(6): e0269827, 2022.
Article in English | MEDLINE | ID: covidwho-1892326
ABSTRACT

INTRODUCTION:

Since the beginning of the pandemic in 2020, COVID-19 has changed the medical landscape. International recommendations for localized prostate cancer (PCa) include deferred treatment and adjusted therapeutic routines. MATERIALS AND

METHODS:

To longitudinally evaluate changes in PCa treatment strategies in urological and radiotherapy departments in Germany, a link to a survey was sent to 134 institutions covering two representative baseline weeks prior to the pandemic and 13 weeks from March 2020 to February 2021. The questionnaire captured the numbers of radical prostatectomies, prostate biopsies and case numbers for conventional and hypofractionation radiotherapy. The results were evaluated using descriptive analyses.

RESULTS:

A total of 35% of the questionnaires were completed. PCa therapy increased by 6% in 2020 compared to 2019. At baseline, a total of 69 radiotherapy series and 164 radical prostatectomies (RPs) were documented. The decrease to 60% during the first wave of COVID-19 particularly affected low-risk PCa. The recovery throughout the summer months was followed by a renewed reduction to 58% at the end of 2020. After a gradual decline to 61% until July 2020, the number of prostate biopsies remained stable (89% to 98%) during the second wave. The use of RP fluctuated after an initial decrease without apparent prioritization of risk groups. Conventional fractionation was used in 66% of patients, followed by moderate hypofractionation (30%) and ultrahypofractionation (4%). One limitation was a potential selection bias of the selected weeks and the low response rate.

CONCLUSION:

While the diagnosis and therapy of PCa were affected in both waves of the pandemic, the interim increase between the peaks led to a higher total number of patients in 2020 than in 2019. Recommendations regarding prioritization and fractionation routines were implemented heterogeneously, leaving unexplored potential for future pandemic challenges.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans / Male Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0269827

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Prostatic Neoplasms / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans / Male Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0269827